N.N. Petrov Research Institute of Oncology Chemotherapy and Innovative Technologies Department
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Baldueva, Irina A
REGATA, NCT05539677: Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

Recruiting
N/A
1000
RoW
N.N. Petrov National Medical Research Center of Oncology
Malignant Solid Tumors, Primary Brain Tumor, Melanoma, Soft Tissue Sarcoma, Colorectal Cancer, Kidney Cancer, Prostate Cancer
12/30
12/30
Protsenko, Svetlana A
UNIVERSE, NCT06640530: Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin

Recruiting
3
392
RoW
BCD-263, Nivolumab, Opdivo
Biocad
Advanced Melanoma, Melanoma (Skin)
12/25
03/27
OCTAVA, NCT05732805: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Active, not recruiting
3
270
RoW
BCD-217, nurulimab+prolgolimab, BCD-100, prolgolimab, Forteca, Placebo
Biocad
Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced
06/24
07/25
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Active, not recruiting
2
174
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
02/28
02/28
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
09/27
09/29
NCT06112808: A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Recruiting
1
300
RoW
BCD-263, Nivolumab, Opdivo
Biocad
Advanced Melanoma
09/24
01/27
Georgiev, Georgy P
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Baldueva, Irina A
REGATA, NCT05539677: Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

Recruiting
N/A
1000
RoW
N.N. Petrov National Medical Research Center of Oncology
Malignant Solid Tumors, Primary Brain Tumor, Melanoma, Soft Tissue Sarcoma, Colorectal Cancer, Kidney Cancer, Prostate Cancer
12/30
12/30
Protsenko, Svetlana A
UNIVERSE, NCT06640530: Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin

Recruiting
3
392
RoW
BCD-263, Nivolumab, Opdivo
Biocad
Advanced Melanoma, Melanoma (Skin)
12/25
03/27
OCTAVA, NCT05732805: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Active, not recruiting
3
270
RoW
BCD-217, nurulimab+prolgolimab, BCD-100, prolgolimab, Forteca, Placebo
Biocad
Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced
06/24
07/25
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Active, not recruiting
2
174
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
02/28
02/28
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
09/27
09/29
NCT06112808: A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Recruiting
1
300
RoW
BCD-263, Nivolumab, Opdivo
Biocad
Advanced Melanoma
09/24
01/27
Georgiev, Georgy P
No trials found

Download Options